Demonstrated Safety Profile in Wet AMD

The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.1

VIEW 1 and VIEW 2: Most common adverse reactions (≥1%)1

1 / 3
Most common adverse reactions in patients with wet AMD receiving  EYLEA® in years 1 and 2, Chart
2 / 3
Most common adverse reactions in patients with wet AMD receiving  EYLEA® in years 1 and 2, Chart
3 / 3
Most common adverse reactions in patients with wet AMD receiving  EYLEA® in years 1 and 2, Chart
3 / 3
Most common adverse reactions in patients with wet AMD receiving  EYLEA® in years 1 and 2, Chart

Most common adverse reactions in patients with wet AMD receiving  EYLEA® in years 1 and 2, Chart

Less common serious adverse reactions reported in <1% of the patients treated with EYLEA
were hypersensitivity, retinal tear, and endophthalmitis.1

VIEW 1 Extension: Most common adverse reactions2

Most common adverse reactions in patients with wet AMD receiving  EYLEA® in year 4, Chart Most common adverse reactions in patients with wet AMD receiving  EYLEA® in year 4, Chart

No new safety signals compared with the known profile of EYLEA in Wet AMD.2

AE, adverse event.

Find out more about all
EYLEA indications

Learn more about Eylea® (aflibercept) Injection, Button Learn more about Eylea® (aflibercept) Injection, Button
Enrollment form for reimbursement process, Icon
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details, Button
Product support syringe, Icon
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works, Button
Downloadable resource for HCPs, Icon
Resources

Get the information you
and your patients need
about EYLEA.

See resources, Button
References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021
  2. Kaiser PK, Singer M, Tolentino M, et al. Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration: VIEW 1 extension study. Ophthalmol Retina. 2017;1(4):304-313. doi:10.1016/j.oret.2017.01.004